Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Innovent will supply sintilimab for the collaborated clinical trial
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
Subscribe To Our Newsletter & Stay Updated
